Ghost Tree Partners Outperforms With These Biotech Shorts – ValueWalk Premium

Ghost Tree Partners Outperforms With These Biotech Shorts

Ghost Tree Partners, the biotech-focused hedge fund, returned -8.6% in March, outperforming the broader market but underperforming the rest of the hedge fund industry.

The HFRI Fund Weighted Composite index fell 8.3% during the first three months of the year.
For more up-to-date hedge fund content, and exclusive access to value-focused hedge fund managers, check out Hidden Value Stocks.
According to the firm's first-quarter letter to investors, Ghost Tree spent much of the second half of the first quarter "making . . .

SORRY!

This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.


X
Saved Articles
X
TextTExtLInkTextTExtLInk